The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Pergantou, Helen ^a   Xafaki, P ^a   Adamtziki, E ^a   Koletsi, P ^a   Komitopoulou, A ^a   Platokouki, H ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8A; COMPLEMENT FACTOR; HYDROXYZINE; IMMUNOGLOBULIN; METHYLPHENIDATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; ATTENTION DEFICIT DISORDER; BLEEDING; DNA DETERMINATION; HEMANGIOENDOTHELIOMA; HEMARTHROSIS; HEMOSTASIS; IMMUNOLOGICAL TOLERANCE; LETTER; MOBILIZATION; NONSENSE MUTATION; ORTHOPEDIC SURGERY; OSTEOID OSTEOMA; PHYSIOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; STOP CODON; VON WILLEBRAND DISEASE; WALKING;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; HUMANS; MALE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VON WILLEBRAND DISEASE, TYPE 3; VON WILLEBRAND FACTOR;

EID: 84860323243     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02799.x     Document Type: Letter

References (10)

1. Franchini M, Gandini G, Giuffrida A, Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008; 14: 645-6.
2. Bergamaschini L, Santagelo T, Fariciotti A, Ciavarella N, Manucci PM, Agostoni A. Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (igG1 and/or IgG4) in the complement-activating capacity of immune complexes. J Immunol 1996; 156: 1256-61.
3. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Blood 1981; 57: 25-31.
4. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.
5. Franchini M, Lippi G, Montagnana M et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coag Fibrin 2009; 20: 225-9.
6. Petratos D, Matsinos G, Pergantou H, Anastasopoulos J, Platokouki H. Osteoid osteoma in a child with severe von Willebrand disease. Haemophilia 2010; 16: 545-66.
7. Mannucci PM, Tamaro G, Narchi G et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987; 39: 467-70.
8. Sucker C, Scharf R, Zotz R. Use of recombinant factor VIIa in inheried and acquired von Willebrand disease. Clin Appl Thromb Hemost 2009; 15: 27-31.
9. Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coag Fibrin 2006; 17: 615-9.
10. Canoso RT, Hutton RA, Deykin D. A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol 1977; 2: 183-91.